![Kevin Fitzgerald](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Förmögenhet: 5 M $ per 2026-09-30
Kevin Fitzgerald currently holds the positions of Independent Director at Ovid Therapeutics, Inc. since 2021 and Chief Scientific Officer & Executive VP at Alnylam Pharmaceuticals, Inc. since 2005.
Dr. Fitzgerald completed undergraduate studies at Cornell University and earned a doctorate from Princeton University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-03-05 | 21 106 ( 0,02 % ) | 5 M $ | 2026-09-30 | |
OVID THERAPEUTICS INC. 0,01 % | 2026-04-17 | 17 578 ( 0,01 % ) | 43 769 $ | 2026-09-30 |
| Företag | Position | Start |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2016-09-01 |
| OVID THERAPEUTICS INC. | Direktör/Styrelseledamot | 2021-10-06 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Ovid Therapeutics, Inc.
 Ovid Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides medicines to children and adults with neurological disorders | Health Technology |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Välj din utgåva
All finansiell information anpassad till den nationella nivån
